| Abstrakt: |
A recent study conducted at the First Hospital of Jilin University in Changchun, China, evaluated the efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with chronic hepatitis C virus (HCV) infection. The study found that the combination treatment was highly effective and safe, with 98.2% of patients achieving sustained virological response at post-treatment week 12. The treatment was effective across different HCV genotypes, suggesting it could be a promising option for HCV treatment in China. The study was funded by Medical Writing and Editorial Assistance and supported by Sichuan Lan-bridge Information Technology Co., Ltd. and Nanjing Sanhome Pharmaceutical Co., Ltd. [Extracted from the article] |
